What is the 13F Pro Quality Score for SHC?

13F Pro ranks Sotera Health Co (SHC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SHC's current score at https://13fpro.ai/research/SHC (free sign-up required for the full ranking).

Which hedge funds own the most SHC stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of SHC include Darsana Capital Partners, Sessa Capital IM, L.P., Sculptor Capital. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/SHC as soon as new 13F filings post.

Where does 13F Pro source SHC data?

All Sotera Health Co fundamentals and ownership data come directly from SEC EDGAR. Sotera Health Co files with the SEC under CIK 1822479. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SHC in?

Sotera Health Co (SHC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SHC research updated on 13F Pro?

SHC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Sotera Health Co(SHC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1822479 SHC stock profile & AI dashboard →

13F Pro Quality Score

59.7/100

Rank #909 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

58.3/100

Profitability

68.3/100

Balance Sheet

52.5/100

Earnings Quality

91.7/100

Free Cash Flow

56.0/100

Institutional Flow

78.5/100

Revenue Scale

52.0/100

Dilution Risk

36.2/100

SHC Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Sotera Health Co (SHC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SHC at 59.7/100 on a 32-signal composite quality model, placing it at rank #909 of 2,879 stocks — the top half of the AI-ranked universe. SHC scores in the top quartile across earnings quality (91.7), institutional flow (78.5). Shareholder dilution risk is elevated at 36.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Sotera Health Co reports quarterly revenue of $280.0M, net income of $26.6M, free cash flow of $-16.7M. Top institutional holders of SHC by reported 13-F value include Darsana Capital Partners, Sessa Capital IM, L.P., Sculptor Capital, based on the most recent SEC filings. SHC trades on the Nasdaq exchange and files with the SEC under CIK 1822479. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SHC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Sotera Health Co directly from SEC EDGAR. Sotera Health Co's 13F Pro composite quality score has ranged between 8 and 67 since 2022, currently 59.7 — a stable long-term trajectory across 52 quarterly and live scoring snapshots.

Revenue

Q1 2026

$280.0M

Net Income

Q1 2026

$26.6M

Free Cash Flow

Q1 2026

$-16.7M

ROIC

Q1 2026

1.5%

D/E Ratio

Q1 2026

3.46

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+10.9% YoY

$1.16BFY 2025

FY20 $818.2MFY21 $931.5MFY23 $1.05BFY25 $1.16B

Net Income

+51.7% YoY

$77.9MFY 2025

FY20 $-38.6MFY21 $116.9MFY23 $51.4MFY25 $77.9M

Operating Income

—FY 2025

FY20 $206.0MFY21 $256.7MFY23 $276.7MFY25 —

EPS (Diluted)

+50.0% YoY

$0.27FY 2025

FY20 $-0.16FY21 $0.41FY23 $0.18FY25 $0.27

Total Assets

+4.2% YoY

$3.26BFY 2025

FY20 $2.76BFY21 $2.79BFY23 $3.13BFY25 $3.26B

Total Debt

-3.5% YoY

$2.15BFY 2025

FY20 $1.82BFY21 $1.74BFY23 $2.23BFY25 $2.15B

Op. Cash Flow

+294.4% YoY

$287.2MFY 2025

FY20 $120.6MFY21 $281.5MFY23 $-147.7MFY25 $287.2M

Metric	FY 2025	FY 2023	FY 2021	FY 2020	FY 2019	FY 2018
Revenue	$1.16B +10.9%	$1.05B +12.6%	$931.5M +13.9%	$818.2M +5.1%	$778.3M	—
Net Income	$77.9M +51.7%	$51.4M -56.0%	$116.9M +402.7%	$-38.6M -85.2%	$-20.9M	—
Operating Income	—	$276.7M +7.8%	$256.7M +24.6%	$206.0M +12.2%	$183.6M	—
EPS (Diluted)	$0.27 +50.0%	$0.18 -56.1%	$0.41 +356.2%	$-0.16 -77.8%	$-0.09	—
Total Assets	$3.26B +4.2%	$3.13B +12.2%	$2.79B +1.0%	$2.76B	—	—
Total Debt	$2.15B -3.5%	$2.23B +28.1%	$1.74B -4.5%	$1.82B	—	—
Operating Cash Flow	$287.2M +294.4%	$-147.7M -152.5%	$281.5M +133.5%	$120.6M -19.1%	$149.0M	—

AI Insight: SHC Financial Trends

Revenue growth momentum stalled in Q1 2026 with sequential decline to $280M after reaching $311M peak in Q3 2025.

• Revenue declined 7.6% sequentially from $303M in Q4 2025 to $280M in Q1 2026.

• Total debt decreased from $2,240M in Q3 2024 to $2,152M in Q1 2026.

• Equity strengthened from $423M in Q2 2024 to $623M in Q1 2026.

⚠ Operating cash flow volatility with sharp drop to $29M in Q1 2026 from $103M in Q4 2025.

⚠ Missing operating income data for recent quarters limits margin visibility.

AI Insight: SHC Ratio Trends

Operating margin collapsed from 30.0% in Q4 2024 to 15.2% in Q1 2026, with ROIC falling from 13.2% to 6.1% over the same period.

• Operating margin declined from 30.0% in Q4 2024 to 15.2% in Q1 2026.

• ROIC dropped from 13.2% in Q4 2024 to 6.1% in Q1 2026.

• Debt-to-equity ratio improved from 5.53 in Q4 2024 to 3.46 in Q1 2026.

• Company experienced negative operating margin of -5.8% in Q1 2025 before partial recovery.

⚠ Operating performance remains well below Q4 2024 peak despite two-quarter recovery from Q1 2025 trough.

⚠ ROIC continues declining trend in latest quarter despite margin stabilization above 15%.

Get alerted when SHC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Sotera Health Co including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SHC

Darsana Capital Partners LP
$372.8M26,000,000 sh
Sessa Capital IM, L.P.
$330.5M23,050,000 sh
Sculptor Capital LP
$311.4M21,717,728 sh
BlackRock, Inc.
$299.0M20,849,579 sh
WARBURG PINCUS LLC
$273.9M19,102,952 sh
GTCR LLC
$182.6M12,735,301 sh
Sachem Head Capital Management LP
$167.0M11,645,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$153.9M10,735,006 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$152.1M10,608,717 sh
JANUS HENDERSON GROUP PLC
$131.4M9,162,191 sh

Fund	Value	Shares
Darsana Capital Partners LP	$372.8M	26,000,000
Sessa Capital IM, L.P.	$330.5M	23,050,000
Sculptor Capital LP	$311.4M	21,717,728
BlackRock, Inc.	$299.0M	20,849,579
WARBURG PINCUS LLC	$273.9M	19,102,952
GTCR LLC	$182.6M	12,735,301
Sachem Head Capital Management LP	$167.0M	11,645,000
VANGUARD CAPITAL MANAGEMENT LLC	$153.9M	10,735,006
VANGUARD PORTFOLIO MANAGEMENT LLC	$152.1M	10,608,717
JANUS HENDERSON GROUP PLC	$131.4M	9,162,191

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SHC on your watchlist

Track score changes the day Sotera Health Co files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SHC a good stock to buy?

13F Pro's AI-powered analysis of Sotera Health Co (SHC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SHC are available on the SHC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SHC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SHC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Sotera Health Co's investment landscape.